Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease

(2017) Enrica Cavedo et al.   Scientific Reports

Methylene blue modulates functional connectivity in the human brain

(2016) Pavel Rodriguez et al.   Brain Imaging and Behavior

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

Defeating Alzheimer's disease and other dementias: a priority for European science and society

(2016) Bengt Winblad et al.   LANCET NEUROLOGY

Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain

(2016) Pavel Rodriguez et al.   RADIOLOGY

Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology

(2016) Taylor W. Schmitz et al.   Nature Communications

Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria

(2015) Zheng-Mei Xiong et al.   AGING CELL

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models

(2015) Valeria Melis et al.   BEHAVIOURAL PHARMACOLOGY

Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum

(2015) Melissa E. Murray et al.   BRAIN

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease

(2015) Charles R. Harrington et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Methylene Blue Improves Brain Mitochondrial ABAD Functions and Decreases Aβ in a Neuroinflammatory Alzheimer’s Disease Mouse Model

(2015) Aya Zakaria et al.   MOLECULAR NEUROBIOLOGY

Combined activation of the energy and cellular-defense pathways may explain the potent anti-senescence activity of methylene blue

(2015) Hani Atamna et al.   Redox Biology

Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity

(2014) Cliona Stack et al.   HUMAN MOLECULAR GENETICS

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteopathic tau seeding predicts tauopathy in vivo

(2014) B. B. Holmes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens

(2014) Mei Huang et al.   PSYCHOPHARMACOLOGY

Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes

(2014) Kang Kwang Lee et al.   Redox Biology

Tau accumulation in the nucleus accumbens in tangle-predominant dementia

(2014) Ito Kawakami et al.   Acta Neuropathologica Communications

Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid

(2013) Heiko Braak et al.   ACTA NEUROPATHOLOGICA

Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration

(2013) K. K. Leung et al.   NEUROLOGY

Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo

(2012) Erin E. Congdon et al.   Autophagy

Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior

(2012) Marina R. Picciotto et al.   NEURON

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

Treatment With Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer's Disease Neuroimaging Initiative

(2011) Lon S. Schneider   ARCHIVES OF NEUROLOGY

The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases

(2011) A. D. Murray et al.   BRAIN

How the 1932 and 1947 mental surveys of Aberdeen schoolchildren provide a framework to explore the childhood origins of late onset disease and disability

(2011) Lawrence J. Whalley et al.   MATURITAS

Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue

(2011) Julio C. Rojas et al.   PROGRESS IN NEUROBIOLOGY

The clinical use of structural MRI in Alzheimer disease

(2010) Giovanni B. Frisoni et al.   Nature Reviews Neurology

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease

(2009) Lisa Mosconi et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

(2009) Susan M. Landau et al.   NEUROBIOLOGY OF AGING

P4-384: Tau Aggregation Inhibitor (TAI) therapy with rember™ changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimer's disease (AD)

(2008) Alison D. Murray et al.   Alzheimers & Dementia